Telix Japan – Telix Luncheon Seminar at WFNMB 2022
2 September 2022 | Corporate Spotlight | Telix Japan hosting Luncheon Seminar at WFNMB
We are pleased to announce that Telix will be hosting a Luncheon Seminar at the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB), to be held at the Kyoto International Conference Center from September 7-11 2022.
- Theme: New Horizon of Theranostics in Asia Pacific Region
- Date: September 9, 2022
- Time: 12:30-13:30 (JST)
The Luncheon will include a presentation from Professor Andrew Scott, Laboratory Head at the Olivia Newton-John Cancer Research Institute
and a panel discussion with:
Prof. Xialoi Lan, Wuhan Union Hospital
Mr. Atsushi Okamoto, CTO, JFE Engineering Corporation
Dr. Shintaro Nishimura, President, Telix Pharmaceuticals Japan K.K.
The event will be chaired by Professor Satoshi Minoshima from the University of Utah and the panel discussion will be moderated by Dr. David Cade, CEO, Telix Asia Pacific.
To view the Luncheon Seminar Program please click here.
If you would like to sign up, send an email to firstname.lastname@example.org
The Role of Patents in Drug Development – Telix in Australian Biotechnology Journal
5 October 2022 | Corporate Spotlight | Telix in Australasian Biotechnology Journal – The Role of Patents in Drug Development
First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Melbourne – 30 September 2022. First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
Melbourne – 28 September 2022. Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate